Lovegra Uses

How times a day do you take this medicine?
sponsored

What is Lovegra?

Lovegra is used to treat men who have erectile dysfunction (also called sexual impotence). Lovegra belongs to a group of medicines called phosphodiesterase 5 (PDE5) inhibitors. These medicines prevent an enzyme called phosphodiesterase type-5 from working too quickly. The penis is one of the areas where this enzyme works.

Erectile dysfunction is a condition where the penis does not harden and expand when a man is sexually excited, or when he cannot keep an erection. When a man is sexually stimulated, his body's normal response is to increase blood flow to his penis to produce an erection. By controlling the enzyme, Lovegra helps to maintain an erection after the penis is stroked. Without physical action to the penis, such as that occurring during sexual intercourse, Lovegra will not work to cause an erection.

Lovegra is also used in both men and women to treat the symptoms of pulmonary arterial hypertension. This is a type of high blood pressure that occurs between the heart and the lungs. When hypertension occurs in the lungs, the heart must work harder to pump enough blood through the lungs. Lovegra works on the PDE5 enzyme in the lungs to relax the blood vessels. This will increase the supply of blood to the lungs and reduce the workload of the heart.

Lovegra is available only with your doctor's prescription.

Lovegra indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Lovegra is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when Lovegra was added to background epoprostenol therapy.

Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II–III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%).

Limitation of Use: Adding Lovegra to bosentan therapy does not result in any beneficial effect on exercise capacity.

How should I use Lovegra?

Use Lovegra suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Lovegra suspension.

Uses of Lovegra in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Use: Labeled Indications

Erectile dysfunction: Lovegra: Treatment of erectile dysfunction.

Pulmonary arterial hypertension: Lovegra: Treatment of pulmonary arterial hypertension (WHO group I; efficacy established predominately in patients with WHO/NYHA functional class II and III) in adults to improve exercise ability and delay clinical worsening.

Off Label Uses

High-altitude pulmonary edema

Based on the 2019 Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness, Lovegra is a recommended option for the prevention and treatment of high-altitude pulmonary edema (as an adjunct to descent, oxygen, or portable hyperbaric therapy). Supplemental oxygen and descent are the mainstays of treatment. For prevention, Lovegra should only be considered for patients with a history of high-altitude pulmonary edema, especially multiple episodes.

Raynaud phenomenon

Data from a meta-analysis and small controlled trials support the use of Lovegra for Raynaud phenomenon related to systemic sclerosis, demonstrating a decrease in the frequency and severity of attacks.

Lovegra description

sponsored

Each film-coated tablet contains Sildenafil citrate equivalent to 50 mg Lovegra.

Each film-coated tablet contains Sildenafil citrate equivalent to 100 mg Lovegra.

Each orodispersible tablet contains Sildenafil citrate equivalent to 50 mg Lovegra.

Excipients/Inactive Ingredients: Film-Coated Tablets: In addition to the active ingredient, Lovegra citrate, each tablet contains the following inactive ingredients: Microcrystalline cellulose, calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose (hypromellose), titanium dioxide (E171), lactose, triacetin, and FD & C Blue #2 aluminum lake [indigo carmine aluminum lake (E132)].

Orodispersible Tablets: In addition to the active ingredient, Lovegra citrate, each orodispersible tablet contains the following inactive ingredients: Microcrystalline cellulose, silica hydrophobic colloidal, croscarmellose sodium, magnesium stearate, indigo carmine aluminium lake (E132), sucralose, mannitol, crospovidone, polyvinyl acetate, povidone, flavouring (contains: Maltodextrin and dextrin), natural flavouring (contains: Maltodextrin, E422 glycerol and E1520 propylene glycol), lemon flavouring (contains: Maltodextrin and E307 alpha tocopherol).

Lovegra dosage

sponsored

Lovegra Dosage

Generic name: Lovegra CITRATE 20mg

Dosage form: tablet, film coated; injection; oral powder

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Lovegra Tablets and

Oral Suspension

The recommended dose of Lovegra is 5 mg or 20 mg three times a day. Administer Lovegra doses 4–6 hours apart.

In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.

Lovegra Injection

Lovegra injection is for the continued treatment of patients with PAH who are currently prescribed oral Lovegra and who are temporarily unable to take oral medication.

The recommended dose is 2.5 mg or 10 mg administered as an intravenous bolus injection three times a day. The dose of Lovegra injection does not need to be adjusted for body weight.

A 10 mg dose of Lovegra injection is predicted to provide pharmacological effect of Lovegra and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose.

Reconstitution of the Powder for

Oral Suspension

  1. Tap the bottle to release the powder.
  2. Remove the cap.
  3. Accurately measure out 60 mL of water and pour the water into the bottle. (Figure 1)

    Figure 1

  4. Replace the cap and shake the bottle vigorously for a minimum of 30 seconds. (Figure 2)

    Figure 2

  5. Remove the cap.
  6. Accurately measure out another 30 mL of water and add this to the bottle. You should always add a total of 90 mL of water irrespective of the dose prescribed. (Figure 3)

    Figure 3

  7. Replace the cap and shake the bottle vigorously for a minimum of 30 seconds. (Figure 4)

    Figure 4

  8. Remove the cap.
  9. Press the bottle adaptor into the neck of the bottle (as shown on Figure 5, below). The adaptor is provided so that you can fill the oral syringe with medicine from the bottle. Replace the cap on the bottle.

    Figure 5

  10. Write the expiration date of the constituted oral suspension on the bottle label (the expiration date of the constituted oral suspension is 60 days from the date of constitution).

Incompatibilities

Do not mix with any other medication or additional flavoring agent.

More about Lovegra (Lovegra)

Consumer resources

Professional resources

Related treatment guides

Lovegra interactions

See also:
What other drugs will affect Lovegra?

Effects of Other Drugs on Lovegra Lovegra Citrate

In Vitro Studies: Lovegra Lovegra metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce Lovegra clearance.

In Vivo Studies: Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma Lovegra concentrations when coadministered with Lovegra citrate (50 mg) to healthy volunteers.

When a single 100 mg dose of Lovegra citrate was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 182% increase in Lovegra systemic exposure (AUC). In addition, coadministration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with Lovegra citrate (100 mg single dose) resulted in a 140% increase in Lovegra Cmax and a 210% increase in Lovegra AUC. Lovegra Lovegra citrate had no effect on saquinavir pharmacokinetics. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole would be expected to have still greater effects, and population data from patients in clinical trials did indicate a reduction in Lovegra clearance when it was coadministered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine).

Coadministration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (400 mg bid) with Lovegra citrate (100 mg single dose) resulted in a 300% (4-fold) increase in Lovegra Cmax and a 1000% (11-fold) increase in Lovegra plasma AUC. At 24 hours the plasma levels of Lovegra were still approximately 200 ng/mL, compared to approximately 5 ng/mL when Lovegra was dosed alone. This is consistent with ritonavirs marked effects on a broad range of P450 substrates. Lovegra Lovegra citrate had no effect on ritonavir pharmacokinetics.

It can be expected that concomitant administration of CYP3A4 inducers, such as rifampin, will decrease plasma levels of Lovegra.

Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of Lovegra citrate.

Pharmacokinetic data from patients in clinical trials showed no effect on Lovegra pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers. The AUC of the active metabolite, N-desmethyl Lovegra, was increased 62% by loop and potassium-sparing diuretics and 102% by nonspecific beta-blockers. These effects on the metabolite are not expected to be of clinical consequence.

Effects of Lovegra Lovegra Citrate on Other Drugs

In Vitro Studies: Lovegra Lovegra is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 mM). Given Lovegra peak plasma concentrations of approximately 1 mcM after recommended doses, it is unlikely that Lovegra citrate will alter the clearance of substrates of these isoenzymes.

In Vivo Studies: When Lovegra citrate 100 mg oral was coadministered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.

No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9.

Lovegra Lovegra citrate (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).

Lovegra Lovegra citrate (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%.

Lovegra Lovegra (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.

Lovegra side effects

See also:
What are the possible side effects of Lovegra?

The following serious adverse events are discussed elsewhere in the labeling:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Safety data of Lovegra in adults were obtained from the 12-week, placebo-controlled clinical study (Study 1) and an open-label extension study in 277 Lovegra-treated patients with PAH, WHO Group I.

The overall frequency of discontinuation in Lovegra-treated patients on 20 mg three times a day was 3% and was the same for the placebo group.

In Study 1, the adverse reactions that were reported by at least 3% of Lovegra-treated patients (20 mg three times a day) and were more frequent in Lovegra-treated patients than in placebo-treated patients are shown in Table 1. Adverse reactions were generally transient and mild to moderate in nature.

Table 1: Most Common Adverse Reactions in Patients with PAH in Study 1 (More Frequent in Lovegra-Treated Patients than Placebo-Treated Patients and Incidence ≥ 3% in Lovegra-Treated Patients)

Placebo, %

(n = 70)

Lovegra 20 mg three times a day, %

(n = 69)

Placebo-Subtracted, %
Epistaxis 1 9 8
Headache 39 46 7
Dyspepsia 7 13 6
Flushing 4 10 6
Insomnia 1 7 6
Erythema 1 6 5
Dyspnea exacerbated 3 7 4
Rhinitis 0 4 4
Diarrhea 6 9 3
Myalgia 4 7 3
Pyrexia 3 6 3
Gastritis 0 3 3
Sinusitis 0 3 3
Paresthesia 0 3 3

At doses higher than the recommended 20 mg three times a day, there was a greater incidence of some adverse reactions including flushing, diarrhea, myalgia and visual disturbances. Visual disturbances were identified as mild and transient, and were predominately color-tinge to vision, but also increased sensitivity to light or blurred vision.

The incidence of retinal hemorrhage with Lovegra 20 mg three times a day was 1.4% versus 0% placebo and for all Lovegra doses studied was 1.9% versus 0% placebo. The incidence of eye hemorrhage at both 20 mg three times a day and at all doses studied was 1.4% for Lovegra versus 1.4% for placebo. The patients experiencing these reactions had risk factors for hemorrhage including concurrent anticoagulant therapy.

In a placebo-controlled fixed dose titration study (Study 2) of Lovegra (starting with recommended dose of 20 mg and increased to 40 mg and then 80 mg all three times a day) as an adjunct to intravenous epoprostenol in patients with PAH, the adverse reactions that were more frequent in the Lovegra + epoprostenol group than in the epoprostenol group (greater than 6% difference) are shown in Table 2.

Table 2: Adverse Reactions (%) in patients with PAH in Study 2 (incidence in Lovegra + Epoprostenol group at least 6% greater than Epoprostenol group)

Lovegra + Epoprostenol

(n = 134)

Epoprostenol

(n = 131)

(Lovegra + Epoprostenol) minus Epoprostenol
Headache 57 34 23
Edema^ 25 13 14
Dyspepsia 16 2 14
Pain in extremity 17 6 11
Diarrhea 25 18 7
Nausea 25 18 7
Nasal congestion 9 2 7
^includes peripheral edema

Lovegra Injection

Lovegra injection was studied in a 66-patient, placebo-controlled study in patients with PAH at doses targeting plasma concentrations between 10 and 500 ng/mL (up to 8 times the exposure of the recommended dose). Adverse events with Lovegra injection were similar to those seen with oral tablets.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of Lovegra (marketed for both PAH and erectile dysfunction). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular Events

In postmarketing experience with Lovegra at doses indicated for erectile dysfunction, serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, pulmonary hemorrhage, and subarachnoid and intracerebral hemorrhages have been reported in temporal association with the use of the drug. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of Lovegra without sexual activity. Others were reported to have occurred hours to days after use concurrent with sexual activity. It is not possible to determine whether these events are related directly to Lovegra, to sexual activity, to the patient's underlying cardiovascular disease, or to a combination of these or other factors.

Nervous system

Seizure, seizure recurrence

Lovegra contraindications

See also:
What is the most important information I should know about Lovegra?

Do not take Lovegra if you are also using a nitrate drug for chest pain or heart problems. This includes nitroglycerin (Nitrostat, Nitrolingual, Nitro-Dur, Nitro-Bid, and others), isosorbide dinitrate (Dilatrate-SR, Isordil, Sorbitrate), and isosorbide mononitrate (Imdur, ISMO, Monoket). Nitrates are also found in some recreational drugs such as amyl nitrate or nitrite ("poppers"). Taking Lovegra with a nitrate medicine can cause a sudden and serious decrease in blood pressure.

During sexual activity, if you become dizzy or nauseated, or have pain, numbness, or tingling in your chest, arms, neck, or jaw, stop and call your doctor right away. You could be having a serious side effect of Lovegra.

Do not take Lovegra more than once a day. Allow 24 hours to pass between doses. Do not take Lovegra while also taking Lovegra, unless your doctor tells you to.

Contact your doctor or seek emergency medical attention if your erection is painful or lasts longer than 4 hours. A prolonged erection (priapism) can damage the penis.

Lovegra can decrease blood flow to the optic nerve of the eye, causing sudden vision loss. This has occurred in a small number of people taking Lovegra, most of whom also had heart disease, diabetes, high blood pressure, high cholesterol, or certain pre-existing eye problems, and in those who smoke or are over 50 years old. It is not clear whether Lovegra is the actual cause of vision loss.

Stop using Lovegra and get emergency medical help if you have sudden vision loss.



Active ingredient matches for Lovegra:

Sildenafil in Vietnam.


Unit description / dosage (Manufacturer)Price, USD
50 mg x 4's$ 0.76
100 mg x 4's$ 1.17
Lovegra 50 mg x 1 Blister x 4 Tablet
Lovegra 50 mg x 1 Bottle 10 Tablet
Lovegra 50 mg x 1 Bottle 30 Tablet
Lovegra 50mg TAB / 4$ 0.76
Lovegra 100mg TAB / 4$ 1.17
LOVEGRA tab 50 mg x 4's (PCI)$ 0.76
LOVEGRA tab 100 mg x 4's (PCI)$ 1.17
Lovegra 50mg TAB / 4$ 0.76
Lovegra 100mg TAB / 4$ 1.17

List of Lovegra substitutes (brand and generic names):

Lupigra 50mg TAB / 96 (Lupin)$ 27.43
Lupigra 100mg TAB / 96 (Lupin)$ 41.14
50 mg x 96's (Lupin)$ 27.43
100 mg x 96's (Lupin)$ 41.14
LUPIGRA TABLET 1 strip / 4 tablets each (Lupin)$ 0.16
LUPIGRA tab 50 mg x 4's (Lupin)$ 1.14
LUPIGRA tab 100 mg x 4's (Lupin)$ 1.71
Lupigra 50mg Tablet (Lupin)$ 0.04
Macsutra 100mg Tablet (Macleods Pharmaceuticals Pvt Ltd)$ 0.87
Powder; Oral; Chromium / Chromium HVP Chelate 1.85 mcg; Copper / Copper Gluconate 0.03 mg; D-Pantothenic Acid / Calcium D-Pantothenate 1.36 mg; Folic Acid 0.01 mg; Nicotinamide 5.48 mg; Vitamin B1 0.11 mg; Vitamin B12 1.48 mcg; Vitamin B2 0.22 mg; Vitamin (Sidus)
Powder; Oral; Chromium / Chromium HVP Chelate 1.85 mcg; Copper / Copper Gluconate 0.03 mg; D-Pantothenic Acid / Calcium D-Pantothenate 1.36 mg; Folic Acid 0.01 mg; Nicotinamide 5.48 mg; Vitamin B1 0.11 mg; Vitamin B12 1.48 mcg; Vitamin B2 0.22 mg; Vitamin (Sidus)
Majegra 100 mg x 1 Blister x 4 Tablet
Manly 50mg TAB / 10
Manly 100mg TAB / 10
MANPIL 100 MG TABLET 1 strip / 4 tablets each (Psychotropics India Ltd)$ 0.18
MANPIL 50 MG TABLET 1 strip / 4 tablets each (Psychotropics India Ltd)$ 0.12
Manpil 100mg Tablet (Psychotropics India Ltd)$ 0.04
Manpil 50mg Tablet (Psychotropics India Ltd)$ 0.03
50 mg x 4's (Pidek)$ 0.95
Manpower 50mg TAB / 4 (Pidek)$ 0.95
MANPOWER tab 50 mg x 4's (Pidek)$ 0.95
Manpower 50mg TAB / 4 (Pidek)$ 0.95
Mar-sildenafil tablet 100.0 mg (Marcan Pharmaceuticals Inc (Canada))
Mar-sildenafil tablet 25.0 mg (Marcan Pharmaceuticals Inc (Canada))
Mar-sildenafil tablet 50.0 mg (Marcan Pharmaceuticals Inc (Canada))
Masterstroke-50 50mg TAB / 4$ 1.24
Maxigra 50 mg x 1 Blister x 1 Tablet
Maxigra 50 mg x 1 Blister x 4 Tablet
Maxigra 100 mg x 1 Blister x 1 Tablet

References

  1. PubChem. "sildenafil". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  2. DrugBank. "sildenafil". http://www.drugbank.ca/drugs/DB00203 (accessed September 17, 2018).
  3. MeSH. "Urological Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Lovegra are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lovegra. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


2 consumers reported time for results

To what extent do I have to use Lovegra before I begin to see changes in my health conditions?
As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Lovegra. To get the time effectiveness of using Lovegra drug by other patients, please click here.
Users%
1 day2
100.0%


4 consumers reported age

Users%
46-602
50.0%
30-451
25.0%
16-291
25.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved